0001567892-20-000040.txt : 20200615 0001567892-20-000040.hdr.sgml : 20200615 20200615113422 ACCESSION NUMBER: 0001567892-20-000040 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200615 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200615 DATE AS OF CHANGE: 20200615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mallinckrodt plc CENTRAL INDEX KEY: 0001567892 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981088325 FISCAL YEAR END: 1225 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35803 FILM NUMBER: 20962305 BUSINESS ADDRESS: STREET 1: 3 LOTUS PARK, THE CAUSEWAY STREET 2: STAINES-UPON-THAMES CITY: SURREY STATE: X0 ZIP: TW18 3AG BUSINESS PHONE: 44-017-8463-6700 MAIL ADDRESS: STREET 1: 3 LOTUS PARK, THE CAUSEWAY STREET 2: STAINES-UPON-THAMES CITY: SURREY STATE: X0 ZIP: TW18 3AG 8-K 1 mnk8-k06152020.htm 8-K Document
false0001567892 0001567892 2020-06-15 2020-06-15



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 15, 2020
 
Mallinckrodt plc

(Exact name of registrant as specified in its charter)
Ireland
001-35803
98-1088325
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
3 Lotus Park, The Causeway, Staines-Upon-Thames
Surrey TW18 3AG, United Kingdom
(Address of principal executive offices) (Zip Code)
 
Registrant's telephone number, including area code:  +44 017 8463 6700
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, par value $0.20 per share
MNK
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 8.01.     Other Events.
On June 15, 2020, Mallinckrodt plc (“Mallinckrodt” or the “Company”) issued a press release confirming that its subsidiary, Mallinckrodt ARD LLC, received a decision from the U.S. Court of Appeals for the District of Columbia on its request for a temporary injunction related to its suit against the U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) regarding the Company’s calculation of Medicaid drug rebates for Acthar Gel® (repository corticotropin injection). A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.
Cautionary Statements Related to Forward-Looking Statements
Statements in this document that are not strictly historical, including statements concerning the dispute between Mallinckrodt, HHS and CMS with regard to Medicaid drug rebates for Acthar Gel; the litigation filed by Mallinckrodt against HHS and CMS in connection with this dispute including any related appeals; the change of the base date AMP for Acthar Gel and the resulting payment of any retroactive non-recurring charges; the impact of such dispute and any such litigation on Mallinckrodt’s ability to fund research and development activities (including COVID-19 related activities) or on its ability to effectuate its proposed opioid settlement; the impact of any of the foregoing on Mallinckrodt’s future financial condition, operating results, and other pending litigation; and any other statements regarding events or developments that Mallinckrodt believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.
There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: the dispute between Mallinckrodt, HHS and CMS, including the outcome of the lawsuit filed by Mallinckrodt and any related appeals, as well as the time and expense of litigating this dispute; the impact of this dispute on Mallinckrodt’s expectations for performance in 2020, as well as the potential retroactive financial impact on Mallinckrodt of an adverse outcome or any other impacts; governmental investigations and inquiries, regulatory actions and lawsuits brought against Mallinckrodt by government agencies and private parties with respect to its historical commercialization of opioids, including the non-binding agreement in principle regarding terms and conditions of a global settlement to resolve all current and future opioid-related claims; scrutiny from governments, legislative bodies and enforcement agencies related to sales, marketing and pricing practices; pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers' reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; the reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers; complex reporting and payment obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; changes in or failure to comply with relevant laws and regulations; Mallinckrodt's and its partners' ability to successfully develop or commercialize new products or expand commercial opportunities; Mallinckrodt's ability to navigate price fluctuations; competition; Mallinckrodt's and its partners' ability to protect intellectual property rights; limited clinical trial data for Acthar Gel; clinical studies and related regulatory processes; product liability losses and other litigation liability; material health, safety and environmental liabilities; potential indemnification liabilities to Covidien pursuant to the separation and distribution agreement; business development activities; retention of key personnel; the effectiveness of information technology infrastructure including cybersecurity and data leakage risks; customer concentration; Mallinckrodt's reliance on certain individual products that are material to its financial performance; Mallinckrodt's ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; complex manufacturing processes; conducting business internationally; Mallinckrodt's ability to achieve expected benefits from restructuring activities; Mallinckrodt's significant levels of intangible assets and related impairment testing; labor and employment laws and regulations; natural disasters or other catastrophic events; Mallinckrodt's substantial indebtedness and its ability to generate sufficient cash to reduce its indebtedness; future changes to U.S. and foreign tax laws or the impact of disputes with governmental tax authorities; the impact of Irish laws; and the impact of the outbreak of the COVID-19 coronavirus.

These and other factors are identified and described in more detail in the “Risk Factors” section of Mallinckrodt's Annual Report on Form 10-K for the fiscal year ended December 27, 2019 and the "Risk Factors" section of Mallinckrodt's Quarterly Report on Form 10-Q for the quarterly period ended March 27, 2020. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.






Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
 
Exhibit
99.1
 
104
 
Cover Page Interactive Data File (embedded within the inline XBRL document).









SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
MALLINCKRODT PLC
 
 
 
 
(registrant)
 
 
 
 
 
Date:
June 15, 2020
 
By:
/s/ Mark J. Casey
 
 
 
 
Mark J. Casey
 
 
 
 
Executive Vice President and Chief Legal Officer



 EX-99.1 2 mnkexhibit99106152020.htm EXHIBIT 99.1 Exhibit
Exhibit 99.1


Mallinckrodt to Proceed with Appeal Despite Appellate Court Decision Denying Temporary Injunction in Ongoing Acthar Gel Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)

-- Company remains committed to opioid settlement in principle but says allowing District Court ruling to stand could adversely impact settlement completion --

-- Appeals Court sets expedited briefing and oral argument schedule --

-- Company continues to explore all options to address its long-term liabilities and risks --

STAINES-UPON-THAMES, United Kingdom - June 15, 2020 - Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced its disappointment with the U.S. Court of Appeals for the District of Columbia decision to deny its request for a temporary injunction preventing the U.S. Centers for Medicare and Medicaid Services (CMS) from enforcing a change in Medicaid drug rebate calculation for Acthar® Gel (repository corticotropin injection). Mallinckrodt had asked for the temporary injunction as it appeals a lower court ruling that allowed CMS to reset the base date average manufacturer price (AMP). The Appeals Court also ordered an expedited briefing and oral argument schedule that will likely lead to fall oral arguments, and potentially a ruling by end of year.

As a result of today’s appeals court ruling, Mallinckrodt will change the base date AMP for Acthar Gel, as directed by CMS. The effect of the change is an immediate recognition of retroactive non-recurring charges (estimated at approximately $650 million through mid-June) and the prospective loss of Acthar Medicaid net sales, which has historically contributed to Acthar Gel net sales of $90 to $100 million annually. The company will continue to appeal the March 16 ruling by the U.S. District Court for the District of Columbia that upheld CMS’ position. Barring other arrangements, the cash payments for retroactive Medicaid rebate charges will be processed over time, in accordance with the normal rebate payment schedule, and the company expects the cash outlays will most likely commence in the fourth quarter of 2020.

Despite the ruling, Mallinckrodt remains committed to ensuring that Medicaid patients have access to Acthar Gel.

“We are disappointed in the appeals court decision not to issue a temporary injunction to prevent CMS from enforcing this change in Medicaid rebate calculations while our case is still under appeal,” said Mark Casey, Executive Vice President and Chief Legal Officer of Mallinckrodt. "We will continue our appeal, which could be decided as early as end of year, and strongly believe that the District Court misinterpreted the statute that governs the Medicaid drug rebate program and failed to hold CMS accountable to the Administrative Procedure Act. CMS twice confirmed in writing its approval of the Acthar Gel Medicaid rebate calculation in use today, before it later reversed its position without giving fair notice or any clear legal basis for doing so.”

In legal filings requesting the temporary injunction, Mallinckrodt warned that the retroactive non-recurring charges - if allowed to stand by the appeals court - “would have a dramatic impact upon the company’s existing financial obligations and its efforts to settle other litigation.” While Mallinckrodt has reached an agreement in principle on a global settlement of opioids litigation, and continues to work collaboratively with the parties involved to expedite a reasonable resolution, the agreement could be in jeopardy if the appeals court upholds CMS’ position. The company continues to explore all options to address its long-term liabilities and risks.

ABOUT MALLINCKRODT
Mallinckrodt ARD LLC is a subsidiary of Mallinckrodt, a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune



and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients.

Mallinckrodt Pharmaceuticals uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
Statements in this document that are not strictly historical, including statements concerning the dispute between Mallinckrodt, HHS and CMS with regard to Medicaid drug rebates for Acthar Gel; the litigation filed by Mallinckrodt against HHS and CMS in connection with this dispute including any related appeals; the change of the base date AMP for Acthar Gel and the resulting payment of any retroactive non-recurring charges; the impact of such dispute and any such litigation on Mallinckrodt’s ability to fund research and development activities (including COVID-19 related activities) or on its ability to effectuate its proposed opioid settlement; the impact of any of the foregoing on Mallinckrodt’s future financial condition, operating results, and other pending litigation; and any other statements regarding events or developments that Mallinckrodt believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.

There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: the dispute between Mallinckrodt, HHS and CMS, including the outcome of the lawsuit filed by Mallinckrodt and any related appeals, as well as the time and expense of litigating this dispute; the impact of this dispute on Mallinckrodt’s expectations for performance in 2020, as well as the potential retroactive financial impact on Mallinckrodt of an adverse outcome or any other impacts; governmental investigations and inquiries, regulatory actions and lawsuits brought against Mallinckrodt by government agencies and private parties with respect to its historical commercialization of opioids, including the non-binding agreement in principle regarding terms and conditions of a global settlement to resolve all current and future opioid-related claims; scrutiny from governments, legislative bodies and enforcement agencies related to sales, marketing and pricing practices; pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers' reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; the reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers; complex reporting and payment obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; changes in or failure to comply with relevant laws and regulations; Mallinckrodt's and its partners' ability to successfully develop or commercialize new products or expand commercial opportunities; Mallinckrodt's ability to navigate price fluctuations; competition; Mallinckrodt's and its partners' ability to protect intellectual property rights; limited clinical trial data for Acthar Gel; clinical studies and related regulatory processes; product liability losses and other litigation liability; material health, safety and environmental liabilities; potential indemnification liabilities to Covidien pursuant to the separation and distribution agreement; business development activities; retention of key personnel; the effectiveness of information technology infrastructure including cybersecurity and data leakage risks; customer concentration; Mallinckrodt's reliance on certain individual products that are material to its financial performance; Mallinckrodt's ability to receive


procurement and production quotas granted by the U.S. Drug Enforcement Administration; complex manufacturing processes; conducting business internationally; Mallinckrodt's ability to achieve expected benefits from restructuring activities; Mallinckrodt's significant levels of intangible assets and related impairment testing; labor and employment laws and regulations; natural disasters or other catastrophic events; Mallinckrodt's substantial indebtedness and its ability to generate sufficient cash to reduce its indebtedness; future changes to U.S. and foreign tax laws or the impact of disputes with governmental tax authorities; the impact of Irish laws; and the impact of the outbreak of the COVID-19 coronavirus.

These and other factors are identified and described in more detail in the “Risk Factors” section of Mallinckrodt's Annual Report on Form 10-K for the fiscal year ended December 27, 2019 and the "Risk Factors" section of Mallinckrodt's Quarterly Report on Form 10-Q for the quarterly period ended March 27, 2020. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.


CONTACTS
Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com

Media
Ron Bartlett
H+K Strategies
Senior Vice President
813-545-2399
ron.bartlett@hkstrategies.com

Government Affairs
Mark Tyndall
Senior Vice President, Government Affairs
& Chief Counsel, Litigation
202-383-0090
mark.tyndall@mnk.com


Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2020 Mallinckrodt. 06/20


 EX-101.SCH 3 mnk-20200615.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 mnk-20200615_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 mnk-20200615_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 mnk-20200615_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Information [Table] Document Information [Table] Document Information, Document [Axis] Document Information, Document [Axis] Document [Domain] Document [Domain] Document Information [Line Items] Document Information [Line Items] Entity Central Index Key Entity Central Index Key Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Written Communications Written Communications Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Entity Emerging Growth Company Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag EX-101.PRE 7 mnk-20200615_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 mnk8-k06152020_htm.xml IDEA: XBRL DOCUMENT 0001567892 2020-06-15 2020-06-15 false 0001567892 8-K 2020-06-15 Mallinckrodt plc L2 001-35803 98-1088325 3 Lotus Park, The Causeway Staines-Upon-Thames TW18 3AG GB 017 8463 6700 false false false false Ordinary shares, par value $0.20 per share MNK NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information Document
Jun. 15, 2020
Document Information [Line Items]  
Entity Central Index Key 0001567892
Entity Incorporation, State or Country Code L2
Written Communications false
Document Type 8-K
Document Period End Date Jun. 15, 2020
Entity Registrant Name Mallinckrodt plc
Entity Address, Address Line One 3 Lotus Park, The Causeway
Entity Address, City or Town Staines-Upon-Thames
Entity Address, Postal Zip Code TW18 3AG
Entity Address, Country GB
City Area Code 017
Local Phone Number 8463 6700
Entity Emerging Growth Company Ordinary shares, par value $0.20 per share
Trading Symbol MNK
Security Exchange Name NYSE
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity File Number 001-35803
Entity Tax Identification Number 98-1088325
Entity Emerging Growth Company false
Amendment Flag false
XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Document and Entity Information Document Sheet http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports mnk8-k06152020.htm mnk-20200615.xsd mnk-20200615_cal.xml mnk-20200615_def.xml mnk-20200615_lab.xml mnk-20200615_pre.xml mnkexhibit99106152020.htm http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 12 0001567892-20-000040-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001567892-20-000040-xbrl.zip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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mnk8-k06152020.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "mnk-20200615_cal.xml" ] }, "definitionLink": { "local": [ "mnk-20200615_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "mnk8-k06152020.htm" ] }, "labelLink": { "local": [ "mnk-20200615_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mnk-20200615_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mnk-20200615.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mnk", "nsuri": "http://www.mallinckrodt.com/20200615", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mnk8-k06152020.htm", "contextRef": "D2020Q2", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationStateCountryCode", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information Document", "role": "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mnk8-k06152020.htm", "contextRef": "D2020Q2", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationStateCountryCode", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.", "label": "Document [Domain]", "terseLabel": "Document [Domain]" } } }, "localname": "DocumentDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_DocumentInformationDocumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Document Information, Document [Axis]", "terseLabel": "Document Information, Document [Axis]" } } }, "localname": "DocumentInformationDocumentAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $IX>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 2ES/4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !*7,]04? WI.X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!3L,P#(9?!>7>.FFAAZC+98@32$A, G&+$F^+:-HH,6KW]K1A MZX3@ 3C&_O/YL^36!&F&B,]Q"!C)8;J9?--8CG7.S3L( M>'MZ?,GK%JY/I'N#\Z_D))T";MAE\FN]O=\],%7QBA>\*<3=3@A9WTK>O"^N M/_RNPGZP;N_^L?%%4+7PZR[4%U!+ P04 " !*7,]0F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( $I&PO=V]R:W-H965T&UL=5;MCILP$'P5Q ,EUMTV2=2YY U33Z+CK7ES M%;)AVDSE+5&=Y.SB2$V=T#1=)@VKVKC8N;6C+';BKNNJY4<9J7O3,/GWP&O1 M[V,2?RR\5+=2VX6DV'7LQG]R_:L[2C-+IBJ7JN&MJD0;27[=QY_(]D!S2W"( MUXKW:C:.[%%.0KS9R;?+/D[MCGC-S]J68.;QX,^\KFTELX\_8]%XTK3$^?BC M^A=W>'.8$U/\6=2_JXLN]_$ZCB[\RNZU?A']5SX>:!%'X^F_\P>O#=SNQ&B< M1:W<;W2^*RV:L8K92L/>AV?5NF<_O,GSD883Z$B@_PF9.\L@Y';^F6E6[*3H M(SELQV1+S=V<[:*["O?.;%Z9U4>1[I*'+3,B#@."SA!D0B2F]B1 40'J MZ-F,3G%ZAM(S1\]G],S;'T3DN$"."N2 OO $(&*)"RQ0@06@KSP!B%CC DM4 M8 GH&T\ (DB**ZQ0A17D$T\"@01\7J,2:\CWC48@ :.P)#'4&W(>8T(7AP2&ULA53O;]HP$/W<_14GM(] #!1()XK$Z ^QMA0-IFJ;]L%-#F(UMC/; M&?#?[Q)H-\5D^Q;G[KV[>_?LD;4.=C)5]K*1.)=]" (;)2BY;>L,%476VDCN MZ&@V@Q02"Y4 W(E?B9XU3GRETVSCN-\6H]LK?15_O,"X:MN]K\!1JABQ7$ M<$5-U^G][NSLE.+'\3_C1EB2D/CF7'HD#SQ-A8I>C(X=9&E4PS*)8X/6-E\_ MH-SG"O76YAP5J<:"\KO5757%H:U;.M+YE6 MK55"1G=SPZJD30F]R^]^N#BZIIMU^K/XIVY_053M9CG6& MGL=T1/TM$DU"SG/YC,;SQOF@!X,AJUOMM42S$6H#MT9O75)X,^/*Z_71Q$)Q M!0./Z[6OG9<\ MLS:GY']ACK+>B+1N(_36M'K]D/5JH"N^@UE,Y<3Z^$34$%V$K0X+PUZW7XU, MJ-NX[/@FY9L_T8 >_?%O4$L#!!0 ( $M&POC"@J"RL.?!U[2=MH'< M3*?'=G^]2=/;T0?QX(.^-#/?3+[YGTP!07FA:9'M23PIY49M"8TQ-E1=88 MO2-W- (^E2L@%RYS^LBE*)V8<[D2BF0TR0@_6L,)]$+*A<> M);1Q 62Q0OR62_I/@=7KO2NDW 2F- )%9CDB./WDG3EY!G\)D<4^3]8K;!V? MDO2>[A/FP1S'A13MK_Z_O,M_HI@M MW7-HT:L&W5!2#D*BT(O&3M0U1'GAA_GUM#P M0>)S6/$HQ:#>S@7WOT3Q U!+ P04 " !+ M7,]0%FTC?T,! \ @ #P 'AL+W=O+N)!NRPH_(WD#+UW?M*(7>>K)W=CP[.UZT)-X%>*X-F[OD.[+^1$ MB@9]H&V:9U>Q49ZQ!/"+[(#3UC](9(J M/Q1[+>0L9\$C!BQ1(WT7,MTU2-XBNUHCY3">0XAS_Y\87=-@!2M7]08L#3EZ MT'&Z#2UV00JK#!1RI AE:_%HB=V(M1VDF!MWX='K>MB+.+&+6>'GR V_KB?) M^.BVA@8MU&\\(##.(50;+^*1=*:W=Y-[#KO7^H&Q=_OJ5-*/&N/'+7\ 4$L# M!!0 ( $M&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'.MDD$*@S 0 +\B>4!7;>FAJ*=>O+;]0-#5B)J$[);J[YMZ44&A M!R\)8LX'LQYT4,CQT>7S%1]_27 M6<]>@C"MA[_)1/TUP.K795]02P,$% @ 2US/4 N/V ,A 0 5P0 !, M !;0V]N=&5N=%]4>7!E&ULM51-3\,P#/TK4Z]HS># 6V[ %>8!'\@ M)&X;-5^RO=']>]QN0V(J8FC;)8GS[/=>$BOS]VT&FG3!1UH4#7-^4(I, T%3 MF3)$0:J$0;.$6*NL3:MK4'>SV;TR*3)$GG+/42SG3U#IM>?)XVZ_IUX4.F?O MC&:7HMI$>T0ZW1.6"'[(H<9ENI&$8O+<"0O)WJ(0E IU@L)Q81]+W>L&$)V% M?UE+5>4,V&3604I*R@C:4@/ P9?4: 3[QNABO?>[TL@O.@BQZKSZD5!>SP=O M/8P;&)!+*K.T!8Q)#PGPG;83UVX=\@J6$Z[];_:'29RZ!=_,W(1TKM05\-_\GR"U!+ 0(4 M Q0 ( $ID !D;V-0&UL4$L! A0#% @ 2ES/4%'P-Z3N M *P( !$ ( !F0$ &1O8U!R;W!S+V-O&UL4$L! M A0#% @ 2ES/4)E&PO=V]R:W-H965T&UL4$L! M A0#% @ 2US/4. M'X92 @ ^@4 !0 ( !R L 'AL M+W-H87)E9%-T&UL4$L! A0#% @ 2US/4+JA.8K7 0 ,@8 M T ( !3 X 'AL+W-T>6QE&PO=V]R:V)O;VLN M>&UL4$L! A0#% @ 2US/4/_ )@B] A0( !H ( ! MOA$ 'AL+U]R96QS+W=O